Accelerating Alzheimer’s therapy innovation: A new horizon in blood-based biomarkers

The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis and treatment.

By Dr. Michael K. Racke, Medical Director, Neurology, Quest Diagnostics • Sept. 9, 2024

Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise

OrsoBio is advancing several weight loss medicines. Elsewhere, Boehringer Ingelheim pushed forward with a geographic atrophy drug and Vaxcyte raised $1.3 billion.

By BioPharma Dive staff • Sept. 6, 2024

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Lilly builds case for weekly insulin shot

New data show Lilly’s longer-lasting insulin matched daily shots in controlling blood sugar, adding to positive findings the company disclosed in May.

By Jonathan Gardner • Sept. 5, 2024

High-dose Spinraza meets study goal; Top Dyne executives exit

A new dose regimen of Biogen's spinal muscular atrophy drug appeared promising, while Denali Therapeutics and Regenxbio charted plans for drug approval applications.

By BioPharma Dive staff • Sept. 4, 2024

Novartis builds out radiopharma production with expansion, new factory

A planned facility in California will boost Novartis’ West Coast supply chain as new uses for the company’s radioligand therapies grow.

By Kristin Jensen • Sept. 4, 2024

A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology

Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

By Jonathan Gardner • Sept. 4, 2024

Vaxcyte’s “best-case” data for pneumococcal vaccine boost shares

The company's value jumped by several billion dollars as trial results showed its experimental shot could match and, in some cases, even outperform Pfizer's market-leading Prevnar 20.

By Delilah Alvarado • Sept. 3, 2024

Sanofi finds a silver lining in mixed MS drug results

Tolebrutinib, which Sanofi acquired in a $3.7 billion deal, failed two studies in people with relapsing disease, but succeeded in a type of multiple sclerosis that has no approved therapies.

By Ben Fidler • Sept. 3, 2024

Script for success: The value of digital insights in pharma

Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.

Sept. 3, 2024

Novo builds heart failure case for semaglutide; Ventyx CFO departs

A new analysis showed semaglutide reduced the risk of worsening heart failure. Elsewhere, the FDA OK’d a vaccine for mpox and a biotech planned layoffs.

By BioPharma Dive staff • Aug. 30, 2024

Keytruda fails lung and skin cancer trials, limiting further expansion

The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.

By Jonathan Gardner • Aug. 29, 2024

J&J submits touted autoimmune disease drug for FDA approval

Nipocalimab is one of several drugs J&J has forecast for multi-billion dollar sales. The company’s initial application is for its use in myasthenia gravis.

By Kristin Jensen • Aug. 29, 2024

Pfizer launches DTC service for migraine, COVID drugs

The platform is similar in concept to a service launched this year by Eli Lilly, and aims to give consumers easier access to Pfizer’s migraine, COVID-19 and flu treatments.

By Delilah Alvarado • Aug. 27, 2024

Lilly rolls out Zepbound vials at a discount price

The launch of a single-use vial form of the popular weight loss medicine could help Lilly improve supply and compete with telehealth companies offering compounded versions.

By Ned Pagliarulo • Aug. 27, 2024

RA Capital-backed startup raises $100M; UCB sells China business

New biotech Navigator is working on drugs for immune diseases. Meanwhile, UCB sold its neurology and allergy business in China, and J&J's Peter Fasolo will retire this year.

By BioPharma Dive staff • Aug. 27, 2024

Regeneron gains European approval for bispecific lymphoma drug

Regulators in Europe granted approval based on remission rates, while the FDA sought more progress in confirmatory trials when it rejected Ordspono.

By Jonathan Gardner • Aug. 26, 2024

FDA to convene immunotherapy panel; Tome scales back operations

Agency advisers will discuss whether use of Keytruda and Opdivo should be limited in gastric cancer. Elsewhere, a buzzy genetic drug startup is exploring “strategic options.”

By BioPharma Dive staff • Aug. 23, 2024

Regeneron confirms FDA won’t approve myeloma drug over manufacturing issues

Company executives had warned investors that a delay was likely due to issues at a facility run by a third-party manufacturer.

By Kristin Jensen • Aug. 21, 2024

Lilly’s tirzepatide cuts diabetes risk, study data show

Treatment with the GLP-1 drug, which Lilly sells as Mounjaro and Zepbound, lowered the risk of Type 2 diabetes progression by 94% versus placebo.

By Ned Pagliarulo • Aug. 20, 2024

As Bristol Myers’ schizophrenia drug nears approval, AbbVie and others hope to provide competition

A new wave of antipsychotics could improve patient adherence. The race to corner this large projected market is already getting tight.

By Kelly Bilodeau • Aug. 19, 2024

Pfizer, BioNTech stumble in effort to develop combination flu, COVID shot

The vaccine didn’t spur a strong enough immune response against a particular flu strain in a Phase 3 trial, leading the companies to ponder adjustments. 

By Delilah Alvarado • Aug. 16, 2024

Lilly opens R&D hub; Ovid and Lexicon lay off staff

Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.

By BioPharma Dive staff • Aug. 13, 2024

Merck bets $700M on an antibody drug’s potential in immune diseases

The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.

By Ben Fidler • Aug. 9, 2024

Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study

Merck stopped a Phase 3 TIGIT study for futility. Elsewhere, shares in Cabaletta Bio sank on safety worries and Vertex secured Casgevy reimbursement in England.

By BioPharma Dive staff • Aug. 8, 2024

Zepbound shortages ease, but Lilly cautions pharmacy availability may remain ‘choppy’

After months of supply strains, Lilly has begun to catch up with demand. Consumers may still need to wait for their prescriptions to be filled, however.

By Delilah Alvarado • Aug. 8, 2024